Green Cross, MacroGenics sign exclusive license agreement to develop and commercialize Herceptin Bio

Published: 2010-07-13 06:57:00

Updated: 2010-07-13 06:57:00

Green Cross Corporation and US-based MacroGenics Inc. announced on July 8 an agreement to grant Green Cross exclusive rights to develop and commercialize MGAH22, a next-generation and Fc-optimized mAB that targets HER2.

Green Cross plans to develop MGAH22 for the treatment of various cancers i...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK